CTXR Stock Price, Citius Pharmaceuticals Quote, Chart

Market Summary

USD0.70-0.01

Market Closed

-1.41%

CTXR Stock Price

View Fullscreen

CTXR RSI Chart

CTXR Valuation

Market Cap

111.4M

Price/Earnings (Trailing)

-2.92

Price/Sales (Trailing)

4.2K

EV/EBITDA

-2.42

Price/Free Cashflow

-3.67

CTXR Price/Sales (Trailing)

CTXR Profitability

EBT Margin

-126727.10%

Return on Equity

-45.06%

Return on Assets

-39.2%

Free Cashflow Yield

-27.27%

CTXR Fundamentals

CTXR Revenue

Revenue (TTM)

25.2K

CTXR Earnings

Earnings (TTM)

-38.2M

Earnings Growth (Yr)

-156.88%

Earnings Growth (Qtr)

7.17%

Breaking Down CTXR Revenue

Last 7 days

4.5%

Last 30 days

-27.1%

Last 90 days

11.1%

Trailing 12 Months

-44%

How does CTXR drawdown profile look like?

CTXR Financial Health

Current Ratio

5.06

CTXR Investor Care

Shares Dilution (1Y)

8.78%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2014	34.6K	29.3K	0	0
2013	22.1K	18.7K	29.1K	0
2012	12.6K	12.9K	15.6K	0
2011	0	0	13.4K	7.6K
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Citius Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Sep 27, 2019	holubiak myron z	bought	500,000	0.8951	558,597	president and ceo
Sep 27, 2019	mazur leonard l	bought	2,000,280	0.8951	2,234,700	executive chairman
Apr 03, 2019	holubiak myron z	bought	200,000	1.545	129,450	president and ceo
Apr 03, 2019	mazur leonard l	bought	1,800,000	1.545	1,165,050	executive chairman

Which funds bought or sold CTXR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 02, 2024	Quent Capital, LLC	unchanged	-	387	2,469	-%
May 01, 2024	CREATIVE FINANCIAL DESIGNS INC /ADV	new	-	224	224	-%
May 01, 2024	BNP PARIBAS FINANCIAL MARKETS	added	88.51	34,529	62,466	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	Blue Trust, Inc.	unchanged	-	692	2,692	-%
Apr 30, 2024	Avior Wealth Management, LLC	new	-	16.00	16.00	-%
Apr 30, 2024	Arkadios Wealth Advisors	unchanged	-	14,080	89,730	0.01%
Apr 30, 2024	Private Advisor Group, LLC	unchanged	-	5,632	35,892	-%
Apr 29, 2024	PRINCIPAL FINANCIAL GROUP INC	reduced	-9.22	1,001	14,042	-%
Apr 29, 2024	Princeton Global Asset Management LLC	unchanged	-	563	3,589	-%

Are Funds Buying or Selling CTXR?

Are funds buying CTXR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CTXR

No. of Funds

Unveiling Citius Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 31, 2024	blackrock inc.	5.3%	8,457,814	SC 13G
Jul 08, 2022	blackrock inc.	1.6%	2,347,292	SC 13G
Feb 15, 2022	armistice capital, llc	1.6%	2,425,000	SC 13G/A
Feb 04, 2022	blackrock inc.	5.6%	8,128,256	SC 13G
Feb 16, 2021	armistice capital, llc	9.99%	6,168,361	SC 13G/A
Feb 14, 2020	armistice capital, llc	9.99%	3,210,927	SC 13G/A
Feb 06, 2020	drill craig a	2.4%	693,600	SC 13G/A

Recent SEC filings of Citius Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Apr 30, 2024	8-K	Current Report
Apr 26, 2024	424B5	Prospectus Filed
Apr 05, 2024	4	Insider Trading
Apr 05, 2024	4	Insider Trading
Apr 05, 2024	8-K	Current Report
Mar 18, 2024	3	Insider Trading
Mar 18, 2024	4	Insider Trading
Mar 18, 2024	8-K	Current Report
Mar 13, 2024	8-K	Current Report
Mar 01, 2024	EFFECT	EFFECT

Peers (Alternatives to Citius Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	47.9B	6.8B	23.52%	-6.94%	-8.03	7	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.3B	2.0B	0.99%	-25.83%	-58.02	9.62	75.20%	68.82%
BMRN	15.7B	2.5B	-4.94%	-13.58%	76.24	6.34	13.74%	186.89%
INCY	12.1B	3.8B	-2.80%	-18.78%	16.19	3.2	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-16.72%	-43.78%	-10.82	14.42	425.83%	18.94%
BBIO	5.2B	107.9M	-4.79%	106.15%	-9.53	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	1.74%	5.10%	-14.81	13.09	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.74%	-39.00%	-10.2	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.55%	-20.97%	-45.79	3.86	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-4.91%	-11.58%	24.31	4.36	85.90%	-14.05%
NVAX	687.2M	983.7M	8.15%	-35.14%	-1.26	0.7	-50.36%	17.16%
CRBP	408.0M	881.7K	0.99%	345.87%	-9.15	466.16	-77.61%	-5.33%
INO	282.8M	4.9M	-1.94%	21.49%	-2.09	58.11	-54.97%	51.71%
IBIO	6.9M	2.1M	-32.65%	86.79%	-0.25	2.14	-13.45%	66.37%

Citius Pharmaceuticals Inc News

Latest updates

Citius Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2014Q2	2014Q1	2013Q3	2013Q2	2013Q1	2012Q3	2012Q2	2012Q1	2011Q4	2011Q3	2011Q2	2011Q1	2010Q4	2010Q3
Revenue	-64.2%	3,360	9,396	13,375	3,200	8,650	3,906	2,950	6,573	2,130	1,250	2,600	1,600	8,000	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-6.0%	97.00	104	110	104	112	114	120	128	138	142	147	135	35.00	44.00	38.00	26.00	25.00	37.00	26.00	24.00	28.00
Current Assets	-17.9%	28.00	34.00	41.00	35.00	42.00	45.00	51.00	58.00	68.00	73.00	117	105	6.00	14.00	9.00	4.00	3.00	8.00	5.00	3.00	7.00
Cash Equivalents	-23.2%	20.00	26.00	33.00	29.00	37.00	42.00	48.00	56.00	65.00	70.00	116	104	4.00	14.00	9.00	4.00	3.00	8.00	5.00	3.00	7.00
Net PPE	-40.4%	854*	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	236*	413*	590*	777*	0.00	0.00
Goodwill	0%	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	2.00	2.00	9.00	2.00	2.00	2.00
Liabilities	-0.9%	12.00	12.00	12.00	12.00	11.00	11.00	10.00	10.00	13.00	10.00	9.00	9.00	10.00	10.00	10.00	4.00	5.00	10.00	-	-	-
Current Liabilities	-3.5%	6.00	6.00	6.00	6.00	5.00	5.00	4.00	4.00	7.00	4.00	4.00	3.00	4.00	4.00	4.00	3.00	4.00	5.00	4.00	3.00	4.00
Shareholder's Equity	-6.7%	85.00	91.00	98.00	92.00	101	103	110	118	125	133	137	126	26.00	34.00	29.00	25.00	23.00	27.00	24.00	24.00	27.00
Retained Earnings	-5.7%	-171	-162	-152	-143	-133	-129	-121	-112	-105	-96.05	-91.09	-85.26	-81.14	-70.59	-66.47	-64.57	-60.14	-53.05	-52.17	-47.76	-44.13
Additional Paid-In Capital	1.2%	256	253	250	235	234	232	231	230	229	228	228	210	106	104	95.00	87.00	80.00	80.00	74.00	69.00	68.00
Shares Outstanding	0.1%	159	159	159	146	146	146	146	146	146	146	96.00	76.00	-	-	-	-	-	-	-	-	-
Minority Interest	0%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	157	-	-	-	240	-	-	-	218	-	-	-	16.00	-	-	-	9.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	9.8%	-6,135	-6,800	-9,582	-7,853	-4,824	-6,332	-7,712	-9,665	-4,651	-5,591	-4,823	-4,271	-9,564	-3,357	-3,991	-4,467	-5,114	-2,907	-3,522	-3,849	-2,158
Share Based Compensation	-0.6%	3,058	3,076	1,174	1,166	1,201	977	1,004	1,021	905	462	374	343	277	249	175	159	220	137	204	204	171
Cashflow From Investing	-	-	-	-	-	-	-	-	-	-	-40,000	-	-	-	-	-	-	-	-	-	-	-
Cashflow From Financing	100.0%	-	-687*	13,799	-	-	-	-	-	-	-	16,797	103,673	500*	8,700	8,171	6,027	106*	6,290	4,834	7.00	16.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CTXR Income Statement

2023-12-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenues
Operating Expenses
Research and development	2,621,910	3,445,515
General and administrative	3,660,728	2,603,287
Stock-based compensation – general and administrative	3,058,185	1,201,081
Total Operating Expenses	9,340,823	7,249,883
Operating Loss	(9,340,823)	(7,249,883)
Other Income
Interest income	253,638	214,549
Gain on sale of New Jersey net operating losses		3,585,689
Total Other Income	253,638	3,800,238
Loss before Income Taxes	(9,087,185)	(3,449,645)
Income tax expense	144,000	144,000
Net Loss	$ (9,231,185)	$ (3,593,645)
Net Loss Per Share - Basic (in Dollars per share)	$ (0.06)	$ (0.02)
Weighted Average Common Shares Outstanding
Weighted Average Common Shares Outstanding, Basic (in Shares)	158,955,935	146,211,130

CTXR Balance Sheet

2023-12-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Dec. 31, 2023	Sep. 30, 2023
Current Assets:
Cash and cash equivalents	$ 20,345,618	$ 26,480,928
Prepaid expenses	7,864,496	7,889,506
Total Current Assets	28,210,114	34,370,434
Property and equipment, net	854	1,432
Operating lease right-of-use asset, net	403,996	454,426
Other Assets:
Deposits	38,062	38,062
In-process research and development	59,400,000	59,400,000
Goodwill	9,346,796	9,346,796
Total Other Assets	68,784,858	68,784,858
Total Assets	97,399,822	103,611,150
Current Liabilities:
Accounts payable	2,647,251	2,927,334
Accrued expenses	276,897	476,300
Accrued compensation	2,430,671	2,156,983
Operating lease liability	224,000	218,380
Total Current Liabilities	5,578,819	5,778,997
Deferred tax liability	6,281,800	6,137,800
Operating lease liability – noncurrent	204,569	262,865
Total Liabilities	12,065,188	12,179,662
Commitments and Contingencies
Stockholders’ Equity:
Preferred stock – $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding
Common stock – $0.001 par value; 400,000,000 shares authorized; 158,966,576 and 158,857,798 shares issued and outstanding at December 31, 2023 and September 30, 2023, respectively	158,967	158,858
Additional paid-in capital	256,037,851	252,903,629
Accumulated deficit	(171,462,564)	(162,231,379)
Total Citius Pharmaceuticals, Inc. Stockholders’ Equity	84,734,254	90,831,108
Non-controlling interest	600,380	600,380
Total Equity	85,334,634	91,431,488
Total Liabilities and Equity	$ 97,399,822	$ 103,611,150

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

CEO	Mr. Leonard L. Mazur
WEBSITE	citiuspharma.com
INDUSTRY	Biotechnology
EMPLOYEES	21

Citius Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Citius Pharmaceuticals Inc? What does CTXR stand for in stocks?

CTXR is the stock ticker symbol of Citius Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Citius Pharmaceuticals Inc (CTXR)?

As of Fri May 03 2024, market cap of Citius Pharmaceuticals Inc is 111.37 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CTXR stock?

You can check CTXR's fair value in chart for subscribers.

What is the fair value of CTXR stock?

You can check CTXR's fair value in chart for subscribers. The fair value of Citius Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Citius Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CTXR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Citius Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether CTXR is over valued or under valued. Whether Citius Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Citius Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CTXR.

What is Citius Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 03 2024, CTXR's PE ratio (Price to Earnings) is -2.92 and Price to Sales (PS) ratio is 4.16 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CTXR PE ratio will change depending on the future growth rate expectations of investors.